Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
June 04, 2023 20:21 ET
|
Mesoblast Limited
NEW YORK, June 04, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, is pleased to announce that it has...
KI-Technologie von Evaxion identifiziert in klinischer Phase-I-Studie zu EVX-01 mit einem längeren progressionsfreien Überleben von Melanompatienten assoziierte Krebsimpfstoffziele
June 04, 2023 16:29 ET
|
Evaxion Biotech
Die klinische Studie zum personalisierten Krebsimpfstoff EVX-01 hat die primären Endpunkte der Sicherheit und Verträglichkeit erreichtBei 8 von 12 mit EVX-01 behandelten Patienten wurden positive...
La technologie d'IA d'Evaxion identifie des cibles de vaccin contre le cancer associées à une survie plus longue des patients sans progression de leur mélanome dans la phase 1 de l'essai clinique du EVX-01
June 04, 2023 16:29 ET
|
Evaxion Biotech
L'essai clinique du vaccin contre le cancer personnalisé EVX-01 satisfait à ses critères principaux d'innocuité et de tolérabilitéRéponse clinique positive démontrée chez huit des douze patients...
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
June 04, 2023 12:45 ET
|
Day One Biopharmaceuticals, Inc.
Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 ...
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023 07:13 ET
|
G1 Therapeutics
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment - - Trilaciclib Enhances Expression of Genes Associated with Memory T...
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
June 03, 2023 17:00 ET
|
Evaxion Biotech
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated...
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
June 03, 2023 16:00 ET
|
Sutro Biopharma, Inc.
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer,...
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
June 03, 2023 14:15 ET
|
Cogent Biosciences, Inc.
- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable...
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2023 14:15 ET
|
Replimune Group Inc
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no...
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
June 03, 2023 12:15 ET
|
NewAmsterdam Pharma Company B.V.
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55...